Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...
With strong sales of its blockbuster immune-based cancer drug, Keytruda, along with vaccine products, Merck reported revenue rose 9% YoY to $15.78 billion, surpassing LSEG’s estimate of $15.20 ...
A trial of the drug in patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma was stopped for "futility", meaning it was likely to fail, the company said.
KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell ...
About 75% of the patients on the vaccine combination had recurrence-free survival, compared with 55.6% on Keytruda alone. Moderna-Merck skin cancer vaccine shows survival benefit in long-term ...
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...